3Weisz G,Leon MB,Holmes DR Jr,et al.Two-year outcomes after sirolimus-eluting stent implantation:results from the sirolimus-eluting stent in de Novo Native coronary lesions (SIRIUS) trial.J Am Coll Cardiol,2006,47(7):1350-1355.
4Kastrati A,Dibra A,Mehilli J,et al.Predictive factors of restenosis after coronary implantation of sirolimus-or paclitaxel-eluting stents.Circulation,2006,113(19):2293-2300.
5Marx SO,Jayaraman T,Go LO,et al.Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.Circ Res,1995,76(3):412-417.
6McMahon LP,Choi KM,Lin TA,et al.The rapamycin-binding domain governs substrate selectivity by mammalian target of rapamycin.Mol Cell Biol,2002,22(21):7428-7438.
7Fingar DC,Salama S,Tsou C,et al.Mammalian cell size is controlled by mTOR and its downstream targets,S6K1 and 4EBP1/eIF4E.Genes Dev,2002,16(12):1472-1487.
8Luo Y,Marx SO,Kiyokawa H,et aL.Rapamycin resistance tied to defective regulation of p27Kip1.Mol cell Biol,1996,16(12):6744-6751.
9Gallo R,Padurean A,Jayaraman T,et al.Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle.Circulation,1999,99(16):2164-2170.
10Polyak K,Lee MH,Erdjument-Bromage H,et al.Cloning of p27Kip1,a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals.Cell,1994,78(1):59-66.
